共 50 条
- [31] Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitroCANCER RESEARCH, 2018, 78 (13)Politz, OliverGruenewald, SylviaWalter, AlexanderSiegel, FranziskaScholz, ArneBender, SebastianKneip, ChristophEllinghaus, Peter
- [32] The discovery of AZD4547: An orally bioavailable, potent and selective N-(5-Pyrazolyl)benzamide FGFR1-3 inhibitorCANCER RESEARCH, 2012, 72Thomas, Andrew P.Theoclitou, Maria-ElenaButtar, DavidRuston, LinetteWrigley, GailDennis, MikeRudge, David A.Coleman, TanyaSmith, RobinGavine, Paul R.Klinowska, TeresaMooney, LorraineBrooks, Nigel
- [33] Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancerONCOTARGET, 2015, 6 (04) : 2009 - 2022Chang, JinjiaWang, ShanshanZhang, ZheLiu, XinyangWu, ZhengGeng, RuixuanGe, XiaoxiaoDai, CongqiLiu, RujiaoZhang, QunlingLi, WenhuaLi, Jin
- [34] Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer modelsCANCER RESEARCH, 2011, 71Gozgit, Joseph M.Wong, Matthew J.Moran, LaurenWardwelll, ScottMohemmad, Qurish K.Narasimhan, Narayana I.Shakespeare, William C.Wang, FrankClackson, TimRivera, Victor M.
- [35] DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivoActa Pharmacologica Sinica, 2021, 42 : 1498 - 1506Meng-di DaiYue-liang WangJun FanYang DaiYin-chun JiYi-ming SunXia PengLan-lan LiYu-ming WangWen-hu DuanJian DingJing Ai
- [36] Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer modelsINTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1346 - 1357Gruenewald, SylviaPolitz, OliverBender, SebastianHeroult, MelanieLustig, KlemensThuss, UweKneip, ChristophKopitz, CharlotteZopf, DieterCollin, Marie-PierreBoemer, UlfInce, StuartEllinghaus, PeterMumberg, DominikHess-Stumpp, HolgerZiegelbauer, Karl
- [37] DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivoACTA PHARMACOLOGICA SINICA, 2021, 42 (09) : 1498 - 1506Dai, Meng-diWang, Yue-liangFan, JunDai, YangJi, Yin-chunSun, Yi-mingPeng, XiaLi, Lan-lanWang, Yu-mingDuan, Wen-huDing, JianAi, Jing
- [38] Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME StudyJOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S342 - S342Lam, W.Nowak, A.Chen, F.Muruganandan, S.Arunachalam, S.Chin, M.Millward, M.Read, C.Murray, K.Creaney, J.Lee, Y. C. G.
- [39] Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysisFRONTIERS IN ONCOLOGY, 2023, 12Zheng, XinyiWang, HangDeng, JunyueYao, MingheZou, XiuheZhang, FanMa, Xuelei
- [40] Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft ModelsCLINICAL CANCER RESEARCH, 2012, 18 (24) : 6658 - 6667Zhang, JingchuanZhang, LinSu, XinyingLi, MingXie, LiangMalchers, FlorianFan, ShuQiongYin, XiaoLuXu, YanPingLiu, KunjiDong, ZhengweiZhu, GuanshanQian, ZiliangTang, LiliZhan, PingJi, QunshengKilgour, ElaineSmith, Paul D.Brooks, A. NigelThomas, Roman K.Gavine, Paul R.